Clinical Trials Spotlight - Fibrolight
New Trial Supported by Behavior, Function & Pain CTSU Working to Treat Fibromyalgia
The Behavior, Function & Pain CTSU is supporting a new clinical trial, currently referred to as Fibrolight, led by Principal Investigator Helen Burgess, PhD, that uses bright light therapy to improve symptom management of fibromyalgia syndrome.
Fibromyalgia is a widespread chronic pain condition that estimates show affects more than 6.5 million Americans. There is currently no known cure for fibromyalgia, but a variety of treatments can control symptoms.
In a pilot study, the study team found that morning bright light treatment improved function and pain in patients with fibromyalgia.
"This improvement may be due to morning bright light therapy having a positive impact on the patient's mood and sleep," explained Burgess. "There are also signs that morning bright light therapy may directly affect pain centers in the brain."
The U-M Fibrolight trial will be testing the effects of morning bright light in a sample size of 60 and will be actively recruiting patients after the New Year.
Questions?
Contact us at CTSOgroup@umich.edu.
The Molecular & Behavioral Neuroscience Institute, 205 Zina Pitcher Place, Ann Arbor, MI 48105
A list of CTSO-CTSU contacts are available in the Personnel Directory.